Background {#Sec1}
==========

In recent decades, the incidence and prevalence of diabetes have increased rapidly \[[@CR1]\], with recent studies estimating that 422 million people worldwide are affected \[[@CR2]\]. In addition to the burden directly imposed by the condition, patients with diabetes mellitus and hyperglycemia have been shown to have increased susceptibility to bacterial infections and poor outcomes, including increased risk for hospitalization, reduced cure rates, and increased mortality due to infection \[[@CR3], [@CR4]\]. Furthermore, patients with diabetes commonly have comorbidities that may further affect their response to treatment; for example, both cardiovascular disease and chronic kidney disease appear to be predictors of lengthened hospital stay and infection-related mortality \[[@CR5]--[@CR7]\].

Ceftolozane/tazobactam, an antibacterial with potent activity against Gram-negative pathogens \[[@CR8], [@CR9]\], is approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of patients with complicated intra-abdominal infections (cIAI) when used in combination with metronidazole and for the treatment of patients with complicated urinary tract infections (cUTI), including pyelonephritis \[[@CR10], [@CR11]\]. Ceftolozane/tazobactam was studied in a large phase 3 clinical trial program (Assessment of the Safety Profile and Efficacy of Ceftolozane/Tazobactam \[ASPECT\]) in patients with cIAI or cUTI. In ASPECT-cIAI (NCT01445665 and NCT01445678), ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in patients with cIAI \[[@CR12]\]. In ASPECT-cUTI (NCT01345929 and NCT01345955), ceftolozane/tazobactam demonstrated efficacy superior to that of high-dose levofloxacin in patients with cUTI \[[@CR13]\].

Herein we present a post hoc investigation of baseline characteristics, efficacy, and safety from patients with or without a reported medical history of diabetes in the phase 3 ASPECT trials. The aims of this evaluation were to examine the baseline characteristics of patients with and without diabetes who were enrolled in the ASPECT trials and to assess whether ceftolozane/tazobactam was safe and effective in treating cIAI and cUTI in patients with diabetes.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Two multicenter, multinational, randomized (1:1 ratio), double-blind, noninferiority trials were conducted from 2011 to 2013 (Merck protocols: CXA-cIAI-10-08, CXA-cIAI-10-09, CXA-cUTI-10-04, and CXA-cUTI-10-05). Studies were conducted in accordance with the principles of Good Clinical Practice and were approved by the appropriate institutional review boards and regulatory agencies \[[@CR12], [@CR13]\]. In ASPECT-cIAI, adults with cIAI in need of surgical intervention were assigned to receive intravenous (IV) ceftolozane/tazobactam 1.5 g plus metronidazole 500 mg every 8 h (q8h) or IV meropenem 1 g plus placebo q8h for 4 to 14 days. In ASPECT-cUTI, adults with cUTI (including pyelonephritis) were assigned to receive IV ceftolozane/tazobactam 1.5 g q8h or IV levofloxacin 750 mg/day for 7 days.

Patients {#Sec4}
--------

Patients enrolled in the trials were classified into subgroups with and without diabetes, based on their reported medical history, and all analyses were evaluated between these two subgroups. Baseline demographics and characteristics were recorded descriptively. Between-group differences were determined, and statistical significance was calculated using the Miettinen and Nurminen method \[[@CR14]\].

Efficacy assessments {#Sec5}
--------------------

In ASPECT-cIAI, clinical cure, defined as complete resolution or significant improvement in signs and symptoms of index infection with no additional antibiotics or surgical intervention, was assessed at the test-of-cure (TOC) visit (24--32 days after study drug start). In ASPECT-cUTI, composite cure, defined as both clinical cure (complete resolution or significant improvement in all signs and symptoms) and microbiologic eradication (reduction in all baseline uropathogens to \<10^4^ CFU/mL in urine culture) was assessed at the TOC visit (5--9 days after the end of therapy). For this analysis, clinical cure and composite cure rates were compared between patients with and without diabetes, with indeterminate responses imputed as clinical failures, and Wilson score intervals were used to calculate confidence intervals.

Safety assessments {#Sec6}
------------------

Safety and tolerability were assessed by recording adverse events (AEs). AEs were categorized by the investigator as treatment related (possibly, probably, or definitely) or not treatment related. Data were recorded descriptively. Between-group differences were determined, and statistical significance was calculated using the Miettinen and Nurminen method \[[@CR14]\].

Analysis populations {#Sec7}
--------------------

The cIAI microbiologic intention-to-treat population included all randomly assigned patients with cIAI with ≥1 baseline intra-abdominal pathogen regardless of receipt of, or susceptibility to, study drug. The cUTI microbiologic modified intention-to-treat population included all randomly assigned patients with cUTI with ≥1 dose of study drug and ≥1 uropathogen at baseline, regardless of susceptibility to study drug. The integrated safety population included all patients with cIAI or cUTI who received any amount of study drug.

Results {#Sec8}
=======

Patient population and disposition {#Sec9}
----------------------------------

The pooled analysis population comprised 979 patients from ASPECT-cIAI and 1068 patients from ASPECT-cUTI \[[@CR12], [@CR13]\], including 245 patients with diabetes and 1802 without diabetes. Patient disposition is shown in Table [1](#Tab1){ref-type="table"}. Patient groups (with diabetes and without diabetes) had similar rates of study completion and study drug completion and similar reasons for discontinuation. In ASPECT-cUTI, negative/contaminated urine culture (12.1% and 18.8%, respectively) was the most common reason for early discontinuation of study drug, which was required per protocol.Table 1Patient disposition (safety population)Disposition, n (%)Diabetes\
*n* = 245No diabetes\
*n* = 1802Patients completing the studies230 (93.9)1726 (95.8)Most common reasons for premature withdrawal from the study AEs5 (2.0)16 (0.9) Patient's decision6 (2.4)29 (1.4)Patients completing study drug200 (81.6)1528 (84.8)Most common reasons for discontinuing study drug AEs8 (3.3)32 (1.8) Patient's decision7 (2.8)36 (2.0) Lack of efficacy5 (2.0)11 (0.6)*AE* adverse event

Baseline characteristics {#Sec10}
------------------------

Baseline demographics and disease characteristics are reported in Table [2](#Tab2){ref-type="table"}. In the subgroups with and without diabetes, most patients were white, and slightly more women than men were included. Patients were evenly distributed between treatment arms in the subgroups with and without diabetes (data not shown).Table 2Patient demographics and disease characteristics at baseline (MITT/cIAI population and mMITT/cUTI population)ParameterDiabetes *n* = 198No diabetes *n* = 1408Difference^a^; *P* valuecIAI, *n* (%)65 (32.8)741 (52.6)---cUTI, *n* (%)133 (67.2)667 (47.4)---Sex, *n* (%) Male73 (36.9)601 (42.7)5.8; 0.12061 Female125 (63.1)807 (57.3)−5.8; 0.12061Age, years Mean (SD)60 (13.9)48 (18.9)---  ≥ 18--\<65, *n* (%)123 (62.1)1099 (78.1)15.9; \<0.00001  ≥ 65--\<75, *n* (%)46 (23.2)166 (11.8)−11.4; \<0.00001  \> 75, n (%)29 (14.6)143 (10.2)−4.5; 0.05581Race, *n* (%) White159 (80.3)1282 (91.1)10.7; \<0.00001 Black0 (0.0)17 (1.2)1.2; 0.12020 Asian30 (15.2)64 (4.5)−10.6; \<0.00001 Other9 (4.5)45 (3.2)−1.4; 0.29496Geographic region, *n* (%) North America17 (8.6)59 (4.2)−4.4; 0.00640 South America26 (13.1)127 (9.0)−4.1; 0.06511 Western Europe3 (1.5)27 (1.9)0.4; 0.69541 Eastern Europe118 (59.6)1095 (77.8)18.2; \<0.00001 Rest of world34 (17.2)100 (7.1)−10.1; \<0.00001Weight, kg Mean (SD)79 (17.2)74 (17.2)−5.28; 0.00003  ≥ 75 kg, *n* (%)113 (57.1)627 (44.5)−12.5; 0.00092BMI, kg/m^2^, mean (SD)29 (5.8)26 (5.4)−3.24; \<0.00001APACHE II score (cIAI), *N* ^b^65740  \< 10, *n* (%)43 (66.2)614 (83.0)−16.8; \<0.0008  ≥ 10, *n* (%)22 (33.8)126 (17.0)Baseline creatinine clearance, *n* (%) Missing1 (0.5)0 (0.0) Normal, ≥80 mL/min101 (51.0)983 (69.8)18.8; \<0.00001 Impairment, \<80 mL/min96 (48.5)425 (30.2)---  Mild, ≥50 to \<80 mL/min64 (32.2)359 (25.5)−6.8; 0.04123  Moderate, ≥30 to \<50 mL/min31 (15.7)63 (4.5)−11.2; \<0.00001  Severe, \<30 mL/min1 (0.5)3 (0.2)−0.3; 0.44038Disease type, *n* (%)^c^ cIAI, *N*65741---  Acute gastric or duodenal perforation4 (6.2)67 (9.0)2.9; 0.43116  Appendiceal perforation or periappendiceal abscess14 (21.5)364 (49.1)27.6; 0.00002  Cholecystitis, including gangrenous21 (32.3)120 (16.2)−16.1; 0.00105  Diverticular disease with perforation or abscess8 (12.3)57 (7.7)−4.6; 0.19036  Traumatic perforation of the intestine0 (0.0)12 (1.6)1.6; 0.30158  Peritonitis8 (12.3)66 (8.9)−3.4; 0.36290  Other intra-abdominal abscess10 (15.4)55 (7.4)−8.0; 0.02388 cUTI, *N*133667---  Pyelonephritis106 (79.7)550 (82.5)2.8; 0.44971  cLUTI27 (20.3)117 (17.5)−2.8; 0.44971  Treatment group, *n* (%)^c^ cIAI, *N*65741---  Ceftolozane/tazobactam + metronidazole32 (49.2)357 (48.2)−1.1; 0.87072  Meropenem33 (50.8)384 (51.8)1.1; 0.87072 cUTI, *N*133667---  Ceftolozane/tazobactam67 (50.4)331 (49.6)−0.8; 0.87444  Levofloxacin66 (49.6)336 (50.4)0.8; 0.87444*APACHE II* Acute Physiology and Chronic Health Evaluation II, *BMI* body mass index, *cIAI* complicated intra-abdominal infection, *cLUTI* complicated lower urinary tract infection, *cUTI* complicated urinary tract infection, *MITT* microbiologic intention-to-treat, *mMITT* modified microbiologic intention-to-treat, *SD* standard deviation^a^Percentage difference calculated for patients with history of diabetes versus those with no history of diabetes^b^Expressed as a percentage of the patients with or without diabetes in the cIAI population only^c^Expressed as a percentage of the patients with or without diabetes in the cIAI or cUTI population

Notable differences between patients with and without diabetes included age, weight, race, and comorbidities (Table [2](#Tab2){ref-type="table"}). Significantly more patients with than without diabetes were 65 years of age or older; patients with diabetes were also significantly more likely (57.1%) to weigh ≥75 kg at baseline than those without diabetes (44.5%). In addition, there was a significantly higher proportion of Asian patients in the subgroup with diabetes than in the subgroup without diabetes. As expected, renal impairment was more common in the subgroup with diabetes (48.5%) than in the subgroup without it (30.2%); 15.7% of patients with diabetes had moderate renal impairment compared with 4.5% of patients without diabetes. In cIAI, a significantly higher percentage of patients with diabetes had Acute Physiologic Assessment and Chronic Health Evaluation II scores ≥10 (33.8% vs 17.0% in patients without diabetes), potentially driven by older age and decreased renal function. Additionally, cholecystitis was significantly more common in patients with diabetes; appendiceal infections were significantly more common in patients without diabetes.

A summary of medical history ongoing at baseline is shown in Table [3](#Tab3){ref-type="table"}. As expected, cardiac, endocrine, and eye disorders were reported at significantly higher incidences in the subgroup with diabetes. For cardiac disorders, the major driver of the difference between patients with and without diabetes was coronary artery disorders (17.2% vs 7.6%); for eye disorders, the major driver was diabetic retinopathy (4.5% vs 0%).Table 3Medical history ongoing at baseline (MITT/cIAI population and mMITT/cUTI population)System organ class, *n* (%)^a^DiabetesNo diabetesDifference^b^; Preferred term*n* = 198*n* = 1408*P* valueCardiac disorders50 (25.3)177 (12.6)−12.7; \<0.00001 Coronary artery disorders34 (17.2)107 (7.6)−9.6; \<0.00001 Heart failures15 (7.6)39 (2.8)−4.8; 0.00045Endocrine disorders17 (8.6)57 (4.0)−4.5; 0.00436 Hypothyroidism14 (7.1)41 (2.9)−4.2; 0.00260Eye disorders14 (7.1)33 (2.3)−4.7; 0.00022 Diabetic retinopathy9 (4.5)0−4.5; \<0.00001Hepatobiliary disorders21 (10.6)82 (5.8)−4.8; 0.01014 Hepatic and hepatobiliary disorders13 (6.6)30 (2.1)−4.4; 0.00030Infections and infestations55 (27.8)228 (16.2)−11.6; 0.00006 Urinary tract infections35 (17.7)119 (8.5)−9.2; 0.00004 Viral infectious disorders10 (5.1)25 (1.8)−3.3; 0.00313Metabolism and nutrition disorders198 (100.0)166 (11.8)−88.2; \<0.00001 Glucose metabolism disorders, including diabetes198 (100.0)16 (1.1)−98.9; \<0.00001 Lipid metabolism disorders31 (15.7)62 (4.4)−11.3; \<0.00001 Obesity13 (6.6)37 (2.6)−3.9; 0.00282Musculoskeletal and connective tissue disorders32 (16.2)114 (8.1)−8.1; 0.00022 Joint disorders23 (11.6)64 (4.5)−7.1; 0.00004Nervous system disorders34 (17.2)99 (7.0)−10.1; \<0.00001 Peripheral neuropathies17 (8.6)1 (0.1)−8.5; \<0.00001Psychiatric disorders22 (11.1)79 (5.6)−5.5; 0.00284 Depressive disorders13 (6.6)33 (2.3)−4.2; 0.00086Renal and urinary disorders67 (33.8)245 (17.4)−16.4; \<0.00001 Chronic kidney disease17 (8.6)19 (1.3)−7.2; \<0.00001 Diabetic nephropathy12 (6.1)0 (0.0)−6.1; \<0.00001 Urolithiases22 (11.1)81 (5.8)−5.4; 0.00397Respiratory, thoracic, and mediastinal disorders28 (14.1)87 (6.2)−8.0; 0.00005 Bronchospasm and obstruction17 (8.6)49 (3.5)−5.1; 0.0007Vascular disorders140 (70.7)390 (27.7)−43.0; \<0.00001 Hypertension131 (66.2)342 (24.3)−41.9; \<0.00001*cIAI* complicated intra-abdominal infection, *cUTI* complicated urinary tract infection, *MITT* microbiologic intention-to-treat, *mMITT* modified microbiologic intention-to-treat^a^Only preferred terms with differences in rates between patients with and without diabetes are presented^b^Percentage difference calculated for patients with history of diabetes compared with those with no history of diabetes

Significantly higher incidences of renal diseases and complications were also associated with diabetes, particularly chronic kidney disease (8.6% in patients with diabetes vs 1.3% in patients without diabetes) and diabetic nephropathy (6.1% vs 0%). The significantly higher incidence of vascular disorders in patients with diabetes (70.7% vs 27.7% in patients without diabetes) was largely driven by the incidence of hypertension (66.2% vs 24.3%). Patients with diabetes also had significantly more ongoing infections and more hepatic, nervous system, and respiratory disorders.

Bacteriology findings across subgroups with and without diabetes were generally similar within each indication (cUTI and cIAI; Table [4](#Tab4){ref-type="table"}). *Escherichia coli* was the most common pathogen in both indications and subpopulations.Table 4Baseline infecting intra-abdominal pathogens and uropathogens (MITT/cIAI population and mMITT/cUTI population)Pathogen,^a^ *n* (%)cIAIcUTIDiabetes\
*n* = 65No diabetes\
*n* = 741Diabetes\
*n* = 133No diabetes\
*n* = 667Gram-negative aerobes46 (70.8)613 (82.7)127 (95.5)637 (95.5) Enterobacteriaceae45 (69.2)577 (77.9)126 (94.7)613 (91.9)   *Escherichia coli*37 (56.9)488 (65.9)99 (74.4)530 (79.5)   *Klebsiella pneumoniae*0 (0.0)70 (9.4)14 (10.5)44 (6.6)  *Pseudomonas aeruginosa*0 (0.0)68 (9.2)1 (0.8)22 (3.3)Gram-positive aerobes38 (58.5)406 (54.8)6 (4.5)42 (6.3)  *Enterococcus faecalis*16 (24.6)79 (10.7)4 (3.0)34 (5.1)  *E. faecium*0 (0.0)74 (10.0)0 (0.0)5 (0.7)  *Staphylococcus aureus*0 (0.0)27 (3.6)2 (1.5)4 (0.6)Gram-negative anaerobes24 (36.9)267 (36.0)0 (0.0)NA  *Bacteroides* spp23 (35.4)228 (30.8)0 (0.0)NAGram-positive anaerobes7 (10.8)92 (12.4)0 (0.0)NA*cIAI* complicated intra-abdominal infection, *cUTI* complicated urinary tract infection, *MITT* microbiologic intention-to-treat, *mMITT* microbiologic modified intention-to-treat, *NA*, not applicable^a^Patients could have had multiple infecting pathogens at baseline

Efficacy {#Sec11}
--------

In general, patients with diabetes had lower cure rates than patients without diabetes (cIAI, 75.4% vs 86.1%, *P* = 0.0196; cUTI, 62.4% vs 74.7%, *P* = 0.1299 \[Fig. [1a](#Fig1){ref-type="fig"}\]). However, cure rates were similar between treatment arms in both indications (Fig. [1b](#Fig1){ref-type="fig"}, c), with the exception of significantly higher composite cure rates for ceftolozane/tazobactam than for levofloxacin (79.5% vs 69.9%, *P* = 0.0048) in patients with cUTI but without diabetes (Fig. [1c](#Fig1){ref-type="fig"}).Fig. 1Clinical cure (cIAI) and composite cure (cUTI) in patients with and without diabetes at test-of-cure in cIAI (MITT population) and cUTI (mMITT population) (**a**). Clinical cure at test-of-cure in cIAI (MITT population) (**b**). Composite cure at test-of-cure in cUTI (mMITT population) (**c**). Values above brackets indicate treatment difference (95% confidence intervals)

Safety {#Sec12}
------

Patients with diabetes had significantly higher rates of AEs (49.0% vs 37.3%) and serious AEs (10.6% vs 4.6%) than patients without diabetes (Table [5](#Tab5){ref-type="table"}). However, rates of treatment-related AEs were similar between patients with and without diabetes (8.2% vs 10.1%, respectively), suggesting comorbidities were responsible for differences in AE rates. Types of AEs were generally similar between patient subpopulations, but the incidences of infections and vascular disorders were significantly higher in patients with diabetes.Table 5Summary of AEs (safety population)Parameter, *n* (%)Diabetes\
*n* = 245No diabetes\
*n* = 1802*P* value^a^Any AE120 (49.0)673 (37.3)0.00046Any serious AE26 (10.6)82 (4.6)0.00007Any treatment-related AE20 (8.2)182 (10.1)0.34038Any treatment-related serious AE0 (0.0)4 (0.2)0.46052Any AE leading to discontinuation of study drug8 (3.3)32 (1.8)0.11411Any treatment-related AE leading to discontinuation of study drug3 (1.2)13 (0.7)0.40162Any AE resulting in death6 (2.4)14 (0.8)0.01256Any treatment-related AE resulting in death0 (0.0)0 (0.0)1.00000System organ class AEs with significant difference between groups Infections and infestations29 (11.8)137 (7.6)0.02277  Difference^a^ (95% CI)−4.2 (−9.0, −0.5) Vascular disorders18 (7.3)69 (3.8)0.01046  Difference^a^ (95% CI)−3.5 (−7.6, −0.7)*AE* adverse event, *CI* confidence interval^a^Calculated for patients with diabetes compared with those without diabetes

Discussion {#Sec13}
==========

In this post hoc analysis of patients with or without a reported medical history of diabetes in the phase 3 ASPECT trials, we have shown that older age, increased weight, and renal impairment are more common in patients with diabetes than in patients without diabetes. In addition, more patients with diabetes had comorbidities and an increased incidence of complicating factors in both cUTI and cIAI, with cardiac, endocrine, and eye disorders reported at significantly higher incidences in the subgroup with diabetes. It has been reported that patients with diabetes are more susceptible to infections and associated complications because of a variety of factors, including but not limited to lower production of interleukins in response to infection and increased virulence of some pathogens in hyperglycemic environments \[[@CR15]\].

In our analysis, clinical and composite cure rates were shown to be lower in patients with diabetes but were generally similar between treatment groups, with the exception of significantly higher composite cure rates in ASPECT-cUTI for ceftolozane/tazobactam than for levofloxacin in patients without diabetes. Rates of AEs were also significantly higher in patients with diabetes but were comparable between treatment groups. Overall, the results of this subgroup analysis confirm previous findings in the published literature demonstrating that diabetes increases the risk for poor clinical outcomes and mortality from infectious disease \[[@CR3], [@CR16]--[@CR19]\]. We can postulate that the high levels of complications (including renal and cardiac disorders and additional ongoing infections) in the patient subgroup with diabetes are likely to have had a negative impact on treatment outcomes and that higher rates of AEs in patients with diabetes were also likely due to comorbidities.

This analysis has several limitations, including the post hoc nature of the calculations, which prohibited any statistical significance surrounding the conclusions. Given that the population with diabetes was not prespecified but was defined post hoc based on medical history, the results are contingent on the accuracy of the data reporting and could be confounded by overestimation or underestimation of this patient subgroup. Furthermore, the patient population in the ASPECT studies may not be reflective of the variety of patients seen in clinical practice. Finally, it must be noted that the correlations seen between AE rates, complicating factors, and poorer outcomes among patients with diabetes may be confounded by other unmeasured factors.

Conclusions {#Sec14}
===========

In this post hoc analysis of two phase 3 studies in patients with cIAI and cUTI, baseline factors associated with diabetes included older age, increased weight, and complicating medical factors. Diabetes was associated with lower cure rates and significantly higher AE rates, likely because of the presence of comorbidities. Despite this, ceftolozane/tazobactam was as effective as comparators in treating cUTI and cIAI in patients with diabetes---a population at increased risk for infections and poor clinical outcomes.
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